Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia
Completed
Conditions studied: Hematologic Malignancy
In brief
The main objective of this study is to assess the safety of administering intravenous (IV) pentamidine for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in adult inpatients with hematologic malignancies and stem cell transplant recipients. There will also be an assessment of patient satisfaction associated with intravenous pentamidine PJP prophylactic therapy.
Key facts
- Study ID
- NCT02669706
- Run by
- University of Illinois at Chicago
- People needed
- 50
- Starts
- 2015-03-01
- Expected to finish
- 2016-06-01
- Last updated by the study team
- 2016-06-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults (18 years or older)
- Hematologic malignancy diagnosis or stem-cell transplant recipient
- Eligible for PJP prophylaxis therapy at time of enrollment as per institutional guidelines in compliance with NCCN guidelines. These patients include:
- Acute myeloid leukemia patients receiving induction and consolidation (first line and relapsed/refractory)
- Acute lymphoid leukemia patients receiving HyperCVAD/R (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, rituximab)
- Lymphoma patients receiving ICE (ifosfamide, carboplatin, etoposide), DA-R-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and other inpatient lymphoma regimens
- Patients receiving other inpatient chemotherapy regimens that are given on a monthly basis
- Patients who have received an allogeneic stem cell transplant
- Have given informed consent
- May have previously received inhaled or IV pentamidine
You may not qualify if…
- Pregnancy
- Prisoners
- Patients with a documented allergy or hypersensitivity to pentamidine.
Where it is running
- University of Illinois Hospital and Health Sciences System — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.